Compare 10X Genomics Inc (TXG) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Health Care Select Sector SPDR Fund — how do they compare? 10X Genomics Inc trades at $82.5 (market cap $10.07B), while Health Care Select Sector SPDR Fund trades at $169.8 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 4.3× 10X Genomics Inc's market cap, and Health Care Select Sector SPDR Fund is more actively traded (11,121,431 versus 5,657,286). Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| TXG | XLV | |
|---|---|---|
Market Cap | $10.07B | $43.48B |
Volume | 5,657,286 | 11,121,431 |
Sector | Health | — |
52-Week High | $97.74 | $175.68 |
52-Week Low | $11.48 | $141.95 |
Typical Hold Time | 92 Days | 100 Days |
Enterprise Value | $9.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
XLV trades at $169.58 with a slight 0.46% daily gain amid bearish technical signals. The ETF faces selling pressure with moving averages indicating downward momentum while oscillators remain neutral. Recent news highlights XLV's competitive expense ratio of 0.08% and defensive healthcare sector positioning. Options activity shows increased put volume, suggesting some investor caution despite the fund's diversification across 61 healthcare stocks.
The healthcare ETF presents a cost-effective defensive play with potential upside if political volatility subsides post-elections. Key risks include sector-specific regulatory pressures and biotech trial failures impacting holdings. Current technical weakness near support at $166 requires monitoring for potential breakdown, though the fund's low fees and broad diversification provide stability during market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
